EBS Q3 2025 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$231M-21.3% YoY

Gross Profit

$139M60.3% margin

Operating Income

$77M33.1% margin

Net Income

$51M22.2% margin

EPS (Diluted)

$0.91

QoQ Revenue Growth

+64.0%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$6M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$879M

Stockholders' Equity

$583M

Cash & Equivalents

$246M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$231M	$294M	-21.3%
Gross Profit	$139M	$164M	-15.1%
Operating Income	$77M	$65M	+18.6%
Net Income	$51M	$115M	-55.4%

Revenue Segments

Product

$222M96%

Contracts and Grants

$9M4%